Researchers and analysts are beginning to ask whether two powerful forces are quietly reshaping how and why people eat: the rise of GLP-1 medications and the constant churn of food trends. What happens when drugs like Ozempic don't just reduce appetite but change how the body processes food, forcing users to rethink nutrition to avoid side effects and maintain balance? Could that shift create new demands the food industry is already preparing to meet? And at the same time, why do consumers continue to chase new diets, ingredients, and health claims month after month? What is driving this persistent search for the next solution, even as advice keeps changing?
We examine whether these developments are connected, how pharmaceutical intervention may be accelerating longer-term shifts in food culture, and what it reveals about the forces shaping modern eating habits. Sylvain Charlebois, professor at Dalhousie University and director of its Agri-Food Analytics Lab, and Samantha King, professor and director of the School of Kinesiology and Health Studies at Queen's University, discuss nutrition, behaviour, and the emerging questions at the intersection of medicine, markets, and consumer choice.